Evidence map›Paper›PMID 34988297›Full record

ArticleBiochemistry and biophysics reports2022

Biochemical characterization of the interaction between KRAS and Argonaute 2.

Jessica J Waninger, Tyler S Beyett, Varun V Gadkari, Ronald F Siebenaler, Carson Kenum, Sunita Shankar, Brandon T Ruotolo, Arul M Chinnaiyan, John J G Tesmer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The Multiplicity of Argonaute Complexes in Mammalian Cells.The Journal of pharmacology and experimental therapeutics · 2023
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jessica J WaningerMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.
Tyler S BeyettLife Sciences Institute, University of Michigan, Ann Arbor, MI, USA.
Varun V GadkariDepartment of Chemistry, University of Michigan, Ann Arbor, MI, USA.
Ronald F SiebenalerDepartment of Medical Education, University of Michigan, Ann Arbor, MI, USA.
Carson KenumMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.
Sunita ShankarMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.
Brandon T RuotoloDepartment of Chemistry, University of Michigan, Ann Arbor, MI, USA.
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.
John J G TesmerDepartments of Biological Sciences and Medicinal Chemistry & Molecular Pharmacology, Purdue University, Indiana, USA.
University of Michigan · USHoward Hughes Medical Institute · USPurdue University West Lafayette · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3M
CELLULAR AND MOLECULAR BIOLOGY AT MICHIGANT32GM007315 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PUTHENVEEDU, MANOJKUMAR A · 1985 to 2021
$12.8M
INTERDEPARTMENTAL TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007767 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ISOM, LORI L. · 1985 to 2019
$10.2M
Structure, function, and inhibition of G protein-coupled receptor kinasesR01HL071818 · NHLBI · UNIVERSITY OF TEXAS AUSTIN · PI TESMER, JOHN · 2004 to 2023
$7.1M
Structure and Function of the LPLA2/LCAT Acyltransferase FamilyR01HL122416 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TESMER, JOHN · 2015 to 2018
$1.9M
GPCR - Linked RhoGEFs in Tumor Growth and MetastasisR01CA221289 · NCI · PURDUE UNIVERSITY · PI TESMER, JOHN · 2018 to 2022
$1.9M
Characterization of growth factor control of Argonaute 2 and RAS interactionF30CA221011 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SIEBENALER, RONALD FRANCIS · 2017 to 2019
$122k
NCI NIH HHS F30 CA221011NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA221289NHLBI NIH HHS R01 HL071818NHLBI NIH HHS R01 HL122416NIGMS NIH HHS T32 GM007315NIGMS NIH HHS T32 GM007767NIGMS NIH HHS T32 GM007863
6 · The paper itself

Abstract

Oncogenic mutations in KRAS result in a constitutively active, GTP-bound form that in turn activates many proliferative pathways. However, because of its compact and simple architecture, directly targeting KRAS with small molecule drugs has been challenging. Another approach is to identify targetable proteins that interact with KRAS. Argonaute 2 (AGO2) was recently identified as a protein that facilitates RAS-driven oncogenesis. Whereas previous studies described the

Identifiers

PMID34988297
PMCPMC8695255
OpenAlexW4200255574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.